Feb 14, 2018

Trial Shows Canakinumab Prevents Cancer and Heart Attacks

Posted by in category: biotech/medical

Doctors implicate chronic inflammation as a cause of heart disease and cancer with some claiming that reducing persistent, low-grade inflammation will reduce these diseases. In fact, a recent clinical trial discovered that the inflammation-lowering drug Canakinumab reduced heart attack and strokes by nearly a fourth and cancer by about half.

More than ever, physicians believe that reducing chronic inflammation will also reduce heart attacks and strokes. Robert A. Harrington, M.D., a Cardiologist with the Department of Medicine at Stanford University, leans toward the inflammatory hypothesis of heart disease, a belief that chronic inflammation is a significant cause of heart disease. According to Dr. Harrington.

“Inflammatory cells and signals drive the healing response to vascular injury, allowing the initiation and growth of atherosclerotic plaque.”

Read more

Comments are closed.